The platform excels in delivering large panels of ultra-potent, functionally diverse antibodies against complex disease targets, especially cell surface receptors and highly conserved proteins. RuiYi's research facility is located in the Zhangjiang Hi-Tech Park in Pudong Shanghai, China.įor more information please visit About arGEN-XĪrGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging its powerful, proprietary SIMPLE Antibody™ platform to generate fully human antibodies with differentiated qualities and outstanding therapeutic potential. RuiYi's executive management team has offices in La Jolla, California while all of RuiYi's discovery efforts are located in Shanghai, China. RuiYi is focused on the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs). ARGX-109 has outstanding neutralization potency for IL-6, a cytokine widely implicated in cancer and autoimmunity. "We believe RuiYi's development strategy of first developing ARGX-109 in China is a highly innovative approach to drug development and will maximize the clinical and commercial potential of ARGX-109."ĪRGX-109 is the first of five preclinical stage human antibody candidates developed by arGEN-X from its SIMPLE Antibody™ platform in the three years since its start of operations. "We are excited to partner our first preclinical program so early in our lifetime as a therapeutic antibody company," added Tim Van Hauwermeiren, Chief Executive Officer of arGEN-X. Furthermore, the addition of this molecule accelerates our growth as an early development stage company in China." "ARGX-109 was carefully selected based on its physical and biologic attributes and its range of potential clinical applications in both inflammatory diseases as well as oncology indications.
"The arGEN-X SIMPLE Antibody™ technology enables novel antibodies with outstanding features of potency, human composition and manufacturability," said Paul Grayson, President and CEO of RuiYi. arGEN-X is also eligible to receive additional payments based on the achievement of certain clinical, regulatory and commercialization milestones and royalties based on worldwide net sales of therapeutic products. Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity.
PAUL ARGEN LICENSE
4, 2012 /PRNewswire/ - RuiYi (formerly Anaphore) and arGEN-X BV announced today that arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X.
The customer refused to file a complaint after the incident and told police he would volunteer no more information until he consulted with an attorney, the incident report stated.LA JOLLA, Calif., BREDA, Netherlands and GHENT, Belgium, Oct. The incident report included statements from Vincent Cleffi claiming the customer acted in "a flirtatious manner" to his receptionist before their confrontation, and he denied making racist statements to the man before officers' arrival. Just before that, Vincent Cleffi was seen in the video telling the man to "take your pictures" and to "go ahead, pull the racial card."īefore the racial slur, the man recording the incident said he had just been threatened in front of the police officers, and Cleffi replied that he had threatened him. The man recording the incident, identified by name in the incident report, said at that point that he felt threatened and believed he had been racially profiled. In the video, Cleffi can be heard using explicit language and a racial slur.
0 kommentar(er)
